The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
Down 43% Over the Last Year, CEO Trims Holdings, Sells 1,200 Shares of Software Stock Stock has declined 43% over the past year, though the CEO retains $27.8 million in direct holdings after the sale.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.
The HBM Bottleneck: 3 Tech Companies Have Locked Up 85% of the Supply of AI's Scarcest Asset Nvidia, Alphabet, and AMD have already bought most of the high bandwidth memory that will be manufactured next year.
2 Mining Stocks to Watch as Carney Courts Global Investors Mark Carney is courting global capital for Canada. Here's why Barrick Gold and Endeavour Mining look attractive to TSX investors right now.
Rubrik CFO Kiran Kumar Choudary Sells $2.5 Million Stock Choudary sold shares under a pre-scheduled trading plan adopted in April. The CFO retains 958,078 shares worth around $100 million.
Insider Sale: CEO Liquidates Nearly 40,000 Shares of Small-Cap Growth Stock Leach exercised 15,142 stock options at $3.99 per share under a pre-established Rule 10b5-1 trading plan, maintaining a direct stake of 823,886 shares worth $32.24 million.
Your RMD Deadline Is Closer Than You Think -- Miss It and Pay Dearly With roughly 15 weeks until New Year's Eve, it's time to begin thinking about your next required minimum distribution.
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.
Lightspeed's 2026 Outlook: Payments-Led Strategy Drives Sustained Revenue Growth This under-the-radar commerce software stock boasts a Superscore of 71 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.
Step Aside, Nvidia: 1 Reason Why Meta Platforms Could Be the Best AI Stock to Buy in 2026. In the long run, the infrastructure powering the AI boom could become commoditized, with more of the value going to the businesses creating applications.
If a Recession Is Coming, History Says This 1 No-Brainer ETF Is the Smartest Buy Right Now Hopefully, a recession is averted, but if one arrives, the Invesco S&P 500 High Dividend Low Volatility ETF could help investors weather the storm.
Home Depot vs. Spotify Technology: Which Consumer Stock Is a Better Buy in 2026? Spotify is hitting record margins and crossing major milestones while Home Depot waits for the housing market to cooperate. The growth profiles tell very different stories for investors right now.
2 Game-Changing AI Stocks That Can Plunge 48% and 54%, According to Select Wall Street Analysts Despite popular belief, optimism about the artificial intelligence (AI) revolution isn’t universal on Wall Street.
This Dividend King Yielding 4X the S&P 500 Looks Like a Buy Right Now PepsiCo stock has frustrated investors for at least five years, but it's starting to look worthy of buying.
1 Top Dividend ETF Worth Loading Up On With $1,000 Right Now This ETF's heavier growth profile makes it an ideal high total return opportunity.
3 Financial Stocks Berkshire Hathaway Owns That I'd Buy Before Buying Berkshire Itself These top Berkshire holdings in the financial sector have great potential during the next few years.
3 Stocks to Buy as an Analyst Sees Semiconductor Spending Surging 88% SK Hynix, Nvidia, and ASML all look like top stocks to own as chip sales are set to soar.
3 High-Yield Dividend Stocks I'd Buy in September With No Hesitation These three dividend stocks yield more than 5%, but strong cash flow, not just the payout, is what makes them worth owning now.
Is Verizon the Year's Best Telecom Stock? Verizon's share price has risen more than 25% since the beginning of 2026.
Why Wall Street Is Becoming Even More Bullish About This Dividend King Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence.
With a Key Vote Failed, What's Next for the Clarity Act? The market structure bill for crypto was seen as an important catalyst for the industry.
Nvidia vs. Broadcom: Whose AI Revenue Actually Grows Faster From Here? Broadcom has higher AI revenue growth projections, but Nvidia's larger and more diversified business could make its growth more durable.
Anthropic Is Expected to Go Public in October. The Brokerages Get Paid Either Way. The two lead advisors generated record revenue in Q2, fueled by the SpaceX IPO. Will the Anthropic IPO have a similar impact?
The Fed Just Hiked Interest Rates. Are There More Hikes on the Way? There are multiple signals to indicate what the Federal Reserve might do next.
Forget Michael Burry's Short Thesis. Here's the Bull Case for Palantir He's Not Talking About. The famous investor sees consulting-industry-like risks in Palantir, but several of the company's operating metrics tell a different story.
I'm Confident This Stock Will Triple by 2031. Here's the 1 Reason I'm So Sure. Lululemon has taken a beating, but its global expansion could be the catalyst that turns today's struggling stock into a 2031 turnaround story.
Is Axsome Therapeutics a Buy on the Dip? The stock slipped about 15% over the past three months.
RingCentral COO Makagon Sells 36,185 Shares for $2.5 Million Sale executed under pre-established Rule 10b5-1 trading plan; Makagon retains a substantial stake worth about $18 million.
Here's What $1,000 Invested in IonQ Stock Could Be Worth by 2030 It's an early mover in a space with massive long-term opportunities, but also intense competition and daunting technical challenges.
Planet Labs CEO's Stake in the Company Drops by Over 100,000 Shares Worth $2.2 Million The provider of global satellite data reported a notable disposition of company stock involving its CEO.
GQRE vs HAUZ: Global Real Estate ETF Showdown GQRE delivers higher returns and yield but costs more to own, while HAUZ offers international diversification with a rock-bottom expense ratio.
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue? One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.
Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript Lacutamab advances toward accelerated approval as ADC pipeline expands.
Payment Giant Visa Is Doubling Down on Stablecoins. Here's What Crypto Investors Need to Know. Stablecoins have picked up a powerful ally. Here's what Visa's latest crypto moves mean for ordinary investors.
